InterMune receives FDA Breakthrough Therapy Designation for pirfenidone InterMune announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. FDA. This designation is reserved for drugs that are intended to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Pirfenidone is an investigational treatment for adult patients with idiopathic pulmonary fibrosis.
Garmin price target raised to $70 from $65 at Citigroup Citigroup raised its price target for Garmin shares to $70 saying the company's fitness band vívofit is well positioned to benefit from the faster than expected growth in the activity monitor category. Citi believes 2M-2.5M activity monitors were shipped in Q1, and it expects strong momentum through 2014 and 2015. It reiterates a Buy rating on Garmin.